RxDoctor Payments Data

Robert Gerber, MD

Pulmonary Disease · Cleveland, OHNPI 1023059110

Payments from drug & device makers

$1,048in general payments, 2019–2025

Across 72 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$764
  • Actelion Pharmaceuticals US, Inc.$65
  • United Therapeutics Corporation$40
  • Jazz Pharmaceuticals Inc.$29
  • Nabriva Therapeutics, PLC$23
  • Regeneron Healthcare Solutions, Inc.$22
  • plus $104 from 7 others

What the payments were for

  • Food & beverage$1,03298%
  • Education$162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,048 in reported general payments places this provider in the 40th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$55,198
Medicare patients
299
Services billed
680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter534$470,026
Breztri AerosphereBudesonide/Glycopyr/Formoterol121$91,412
TezspireTezepelumab-Ekko11$50,727
Breo ElliptaFluticasone/Vilanterol109$50,220
Dupixent PenDupilumab12$44,526
Spiriva RespimatTiotropium Bromide58$40,450
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr47$39,300
Advair HfaFluticasone Propion/Salmeterol60$25,276
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$20,966
Combivent RespimatIpratropium/Albuterol Sulfate35$17,517
DuleraMometasone/Formoterol49$17,304
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate55$16,022
Spiriva HandihalerTiotropium Bromide18$13,063
Albuterol Sulfate HfaAlbuterol Sulfate486$12,796
Fluticasone-SalmeterolFluticasone Propion/Salmeterol129$11,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$764$563,094707 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$15$78,933126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →